IsoPlexis: Funding, Investors & Team (Oct 2026)
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.
IsoPlexis has raised $210M across 2 funding rounds on record, the most recent a Post-IPO Equity of $125M announced in Oct 2021.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
IsoPlexis Company Profile and Key Stats
Latest funding round on record: Oct 2021.
IsoPlexis Funding Rounds
IsoPlexis raised $85.0M in a Series D announced in Jan 2021.
9 months later, a Post-IPO Equity of $125M was announced in Oct 2021.
IsoPlexis Founders and Leadership Team
Contact details for the IsoPlexis team: 1 of 1 has an email address on file.
Start 14-day free trial →IsoPlexis Funding Compared to Other Biotechnology Startups
IsoPlexis' latest round of $125M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like IsoPlexis in Biotechnology and Branford
Companies Similar to IsoPlexis
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
IsoPlexis Funding FAQs
What does IsoPlexis do?
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.
How much funding has IsoPlexis raised?
IsoPlexis has raised $210M across 2 rounds on record. The most recent is a Post-IPO Equity of $125M announced in Oct 2021.
When did IsoPlexis last raise funding?
IsoPlexis' most recent funding round on record is a Post-IPO Equity of $125M, announced in Oct 2021.
Who is the CEO of IsoPlexis?
Sean Mackay is listed as CEO at IsoPlexis.
Where is IsoPlexis headquartered?
IsoPlexis is based in Branford, Connecticut, United States.
How many employees does IsoPlexis have?
IsoPlexis is in the 251-500 employee band.
How does IsoPlexis' funding compare to other Biotechnology startups?
IsoPlexis' latest round of $125M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's IsoPlexis Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for IsoPlexis is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.